logo
Call for urgent need for genetic blood disorders awareness

Call for urgent need for genetic blood disorders awareness

Hans India20-05-2025

Vijayawada: Minister for Health, Medical, and Family Welfare Y Satya Kumar Yadav on Monday stressed the critical need for increased public awareness regarding genetic blood disorders like Thalassemia, Sickle Cell Anaemia and Haemophilia.
He was speaking at the inauguration of a two-day 'Orientation Training on Advanced Modalities in Diagnosis and Treatment of Blood Diseases' programme here on Monday, jointly organised by National Health Mission and Haemophilia Society, aims at equipping healthcare professionals with the latest knowledge in diagnosing and treating these conditions.
The Minister highlighted the prevalence of these genetic disorders in the State, stating Andhra Pradesh has approximately 1,900 individuals suffering from Haemophilia, and roughly 2,100 people are battling Thalassemia, with a similar number affected by Sickle Cell Anaemia.'
'The State government is committed to identifying affected individuals and providing them with regular, free blood transfusions,' the Minister affirmed. He noted that five Integrated Centers for Hemoglobinopathy and Haemophilia (ICHH) across the State are already conducting preliminary diagnostic tests. Once a diagnosis is confirmed, the government provides free treatment and medicines.
Beyond medical treatment, the State government is also providing a monthly pension of Rs 10,000 to those afflicted with Thalassemia, Sickle Cell Anaemia, and Haemophilia.
Satya Kumar Yadav also provided an update on the ongoing Sickle Cell Anaemia screening programme in tribal areas, targeting individuals under 40 years old. 'Out of 1.9 million people requiring screening in these areas, we have screened 1.05 million so far, and the process is continuing,' he stated. He revealed that over 19,000 carriers have been identified, and 2,100 individuals have been diagnosed with the disease. Following genetic screening for Sickle Cell Anaemia, identification cards are being issued to those diagnosed.
Minister Yadav also shared that Bhuvaneswari, wife of Chief Minister N Chandrababu Naidu, has undertaken a fundraising initiative in Vijayawada for Thalassemia patients. He mentioned the emergence of new technologies like gene editing, expressing confidence in the expertise of professors in government hospitals to provide high-quality services to economically disadvantaged patients.
Dr Kameswara Prasad (APSACS APD in-charge), Dr Prasanna (Joint Director), Dr Devi (State Immunisation Officer), Dr NBSV Prasad (Secretary, Haemophilia Society Vijayawada Chapter), nodal officers for Sickle Cell Anaemia, nodal officers from the five ICHH centers, Dr Ramachandra Raju, Dr YD Ramarao, and other medical professionals also participated.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Carlyle group exits Indegene; sells 10.2% stake for Rs 1,447 crore
Carlyle group exits Indegene; sells 10.2% stake for Rs 1,447 crore

Economic Times

time14 minutes ago

  • Economic Times

Carlyle group exits Indegene; sells 10.2% stake for Rs 1,447 crore

Global investment firm Carlyle group on Wednesday exited Indegene by divesting its entire 10.2 per cent stake in digital healthcare services for Rs 1,447 crore through open market transactions. ADVERTISEMENT According to the bulk deal data available on the NSE, US-based Carlyle group, through its arm CA Dawn Investments, sold more than 2.44 crore shares, amounting to a 10.20 per cent stake in Indegene. The shares were offloaded in the price range of Rs 591.02-591.84 apiece, taking the combined transaction value to Rs 1,447.17 crore. Meanwhile, Premji Invest's affiliate PI Opportunities AIF V, Capital group, Societe Generale, Luxembourg-based Eastbridge Group and Abakkus Asset Manager cumulatively bought 1.06 crore shares or 4.42 per cent stake in Indegene for Rs 627 crore. The shares were picked up in the price range of Rs 591-591.48 apiece, taking the aggregate deal value to Rs 626.85 crore. Details of the other buyers of Indegene's shares could not be ascertained on the National Stock Exchange (NSE). ADVERTISEMENT Shares of Indegene declined 4.07 per cent to close at Rs 594.50 per piece on the NSE. PE firm Carlyle group's clocked an impressive 31 per cent internal rate of return over a four-year period. This highly profitable divestment marks a pivotal moment, underscoring the immense potential of India's digital healthcare sector. ADVERTISEMENT In April 2021, Carlyle invested USD 122 million (Rs 917 crore) in Indegene by acquiring 45.5 million shares at Rs 201 each on the stock exchanges. Carlyle executed a phased exit as Indegene scaled its global operations and went public in May 2024. The shares were sold by the PE firm at Rs 452 apiece during the initial public offering, at Rs 618 per share in December 2024, and the final tranche at about Rs 591 each in June 2025, enabling Carlyle to secure significant returns amidst varying market conditions. (You can now subscribe to our ETMarkets WhatsApp channel)

Carlyle group exits Indegene; sells 10.2% stake for Rs 1,447 crore
Carlyle group exits Indegene; sells 10.2% stake for Rs 1,447 crore

Time of India

time17 minutes ago

  • Time of India

Carlyle group exits Indegene; sells 10.2% stake for Rs 1,447 crore

Global investment firm Carlyle group on Wednesday exited Indegene by divesting its entire 10.2 per cent stake in digital healthcare services for Rs 1,447 crore through open market transactions. According to the bulk deal data available on the NSE, US-based Carlyle group, through its arm CA Dawn Investments, sold more than 2.44 crore shares , amounting to a 10.20 per cent stake in Indegene. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like コンピュータでゲームをするのが好きなら、この新しいアドベンチャーゲームは必ずプレイすべきです。 アドベンチャーゲーム ゲームをプレイ Undo The shares were offloaded in the price range of Rs 591.02-591.84 apiece, taking the combined transaction value to Rs 1,447.17 crore. Play Video Pause Skip Backward Skip Forward Unmute Current Time 0:00 / Duration 0:00 Loaded : 0.00% 0:00 Stream Type LIVE Seek to live, currently behind live LIVE Remaining Time - 0:00 1x Playback Rate Chapters Chapters Descriptions descriptions off , selected Captions captions settings , opens captions settings dialog captions off , selected Audio Track default , selected Picture-in-Picture Fullscreen This is a modal window. Beginning of dialog window. Escape will cancel and close the window. Text Color White Black Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Text Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Opaque Semi-Transparent Transparent Caption Area Background Color Black White Red Green Blue Yellow Magenta Cyan Opacity Transparent Semi-Transparent Opaque Font Size 50% 75% 100% 125% 150% 175% 200% 300% 400% Text Edge Style None Raised Depressed Uniform Drop shadow Font Family Proportional Sans-Serif Monospace Sans-Serif Proportional Serif Monospace Serif Casual Script Small Caps Reset restore all settings to the default values Done Close Modal Dialog End of dialog window. Meanwhile, Premji Invest's affiliate PI Opportunities AIF V, Capital group, Societe Generale, Luxembourg-based Eastbridge Group and Abakkus Asset Manager cumulatively bought 1.06 crore shares or 4.42 per cent stake in Indegene for Rs 627 crore. The shares were picked up in the price range of Rs 591-591.48 apiece, taking the aggregate deal value to Rs 626.85 crore. Live Events Details of the other buyers of Indegene's shares could not be ascertained on the National Stock Exchange (NSE). Shares of Indegene declined 4.07 per cent to close at Rs 594.50 per piece on the NSE. PE firm Carlyle group's clocked an impressive 31 per cent internal rate of return over a four-year period. This highly profitable divestment marks a pivotal moment, underscoring the immense potential of India's digital healthcare sector. In April 2021, Carlyle invested USD 122 million (Rs 917 crore) in Indegene by acquiring 45.5 million shares at Rs 201 each on the stock exchanges. Carlyle executed a phased exit as Indegene scaled its global operations and went public in May 2024. The shares were sold by the PE firm at Rs 452 apiece during the initial public offering, at Rs 618 per share in December 2024, and the final tranche at about Rs 591 each in June 2025, enabling Carlyle to secure significant returns amidst varying market conditions.

T.N. Scientists Awards for 2022 and 2023 announced
T.N. Scientists Awards for 2022 and 2023 announced

The Hindu

time23 minutes ago

  • The Hindu

T.N. Scientists Awards for 2022 and 2023 announced

The Tamil Nadu State Council for Science and Technology has announced the awardees of the Tamil Nadu Scientist Award for 2022 and 2023. The award is given to scientists from various disciplines including agriculture, biology, chemical sciences; environmental sciences; engineering and technology; mathematics; medicine; physics; social sciences and veterinary sciences. The award includes a cash prize of Rs. 50,000 and a citation. Heads of the research and educational institutions in the state nominate candidates for the awards. The council has constituted an advisory committee of experts for the award in each discipline. TNSCST member secretary S. Vincent said as many as 73 nominations were received for 2022. For the year 2023, the council received 96 nominations. The advisory committee has selected 12 scientists, one from each discipline.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store